Citations

Clear

171 citation(s) found for "Parsons, SK".

NOTQ-04 NEUROCOGNITIVE OUTCOMES IN PATIENTS WITH BRAIN METASTASES: A SYSTEMATIC REVIEW OF PAST FINDINGS AND FUTURE DIRECTIONS
Dargham, Tarek Bou, Batich, Kristen, Gehring, Karin , Dietrich, Jorg, Mullikin, Trey, Hattangadi-Gluth, Jona, Brown, Paul D, Mehta, Minesh, Vaios, Eugene , Dargham, Tarek Bou , Winter, Sebastian Friedrich , Parsons, Michael , Dietrich, Jörg , Reitman, Zachary J. , Floyd, Scott , Kirkpatrick, John P. , Sperduto, Paul W. , Hattangadi‐Gluth, Jona A. , Shih, Helen A. , Sulman, Erik P. , Peters, Katherine B.

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.053 Get It

Abstract Background Multi-modality therapy has improved survival for many patients with brain metastases. However, neurocognitive sequelae remain a challenge. While advances in radiotherapy have reduced toxicity, the potential interaction with targeted therapy and immunotherapy and the consequent impact on neurocognitive outcomes remain poorly defined. We appraised the current evidence on neurocognitive outcomes in the era of modern combined-modality therapy. Methods This systematic review adhered to PRISMA guidelines and included clinical trials reporting neurocognitive outcomes in patients with brain metastases receiving radiotherapy ± concurrent systemic therapies. Studies published through December 31, 2024 were identified through PubMed/Medline, EMBASE, and Web of Science using pre-defined MeSH term-based search strings. Results 39 studies from 1997-2024 involving 6,617 patients met inclusion criteria (n = 27 whole-brain radiotherapy [WBRT]; n = 12 radiosurgery), including six studies evaluating combined-modality therapy in 1,161 patients. Baseline cognitive evaluation was performed inconsistently, but neurocognitive deficits were frequently observed prior to treatment. Most randomized trials reported improved cognitive outcomes and quality of life with advanced radiotherapy techniques (e.g., hippocampal avoidance, radiosurgery) vs WBRT. Among 20 randomized trials comparing radiotherapy with or without a concurrent investigational systemic therapy, only four included neurocognitive assessments. There was no evidence of cognitive sequelae with combined-modality therapy, though evaluable trials were limited due to inconsistent reporting of neurocognitive functioning. Conclusion As survival improves in patients with brain metastases, preserved cognition is an important outcome measure. The lack of neurocognitive endpoints in pivotal brain metastasis trials represents a critical evidence gap. The interaction between radiotherapy and novel systemic therapies, and their combined effects on neurocognition, remain unknown. To address this, we recommend 1) integrating sensitive, pragmatic, and tailored neurocognitive assessments into oncology trials to quantify additive toxicity, 2) early and systematically incorporating neuropsychology into care pathways, 3) expanding radiation dose-sparing and radioprotective strategies, and 4) evaluating the utility of cognitive rehabilitation programs.
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update
Nahleh, Zeina , Alfano, Catherine M. , Somerfield, Mark R. , Lee, Janie M. , Hieken, Tina J. , Magnuson, Allison , Rao, Ruta , Chew, Helen K., Chia, Stephen , Harvey, Brittany , Landsberger, Ellen , Mwanzi, Sitna , Parsons, Heather A. , Patt, DA , Sung, Hyuna , Rao, Ruta , Chia, Stephen K L , Harvey, Brittany E , Lim, Bora , Mwanzi, Sitna Ali , Parsons, Heather A , Sukumar, Jasmine S , Sung, Hyuna , Werutsky, Gustavo , Lustberg, Maryam , Hieken, Tina J , Alfano, Catherine M , Chew, Helen K. , Lim, Bora , Lustberg, Maryam B.

Mayo Clinic

Journal of Clinical Oncology | July 16, 2026 | Volume: 44 | Issue: 30 | Pages: 2953-2971

10.1200/jco-26-01700 | PMID 42462191 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology . ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment. METHODS ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated. RECOMMENDATIONS The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at a high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance. Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer .
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma
Wang, Chang , 吴得红, Tzankov, Alexandar, Møller, Michael , Visco, Carlo , Hsi, Eric D. , Zhao, Xiaoxian , Lv, Beibei, Wang, Bangchen , Yao, Shuna, Chiu, April , Dybkær, Karen , Bhagat, Govind , Montes-Moreno, Santiago, Pan, Zenggang , Bernal‐Mizrachi, Leon , Krieken, J Han JM van, Choi, William W.L., Tam, Wayne , Chen, Weina , Ponzoni, Maurilio, Ferreri, Andrés J.M. , Khajouei, Farzaneh , Sikkink, Kristin , Schmitt, Anthony D. , Xu-Monette, Zijun Y , Møller, Michael Boe , Visco, Carlo , Hsi, Eric D , Lv, Beibei , Wang, Bangchen , Chiu, April , Dybkaer, Karen , Bhagat, Govind , Chen, Weina , Parsons, Benjamin M , Khajouei, Farzaneh , Sikkink, Kristin , Li, Yong , Young, Ken H , Xu‐Monette, Zijun Y. , Tzankov, Alexandar , Cao, Xin , Zu, Youli , Montes‐Moreno, Santiago , Krieken, J. Han van , Ponzoni, Maurilio , Parsons, Benjamin M. , Li, Yong , Hastie, Alex R. , Young, Ken H.

Mayo Clinic

Blood Advances | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026019675 | PMID 42308239 Get It

Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, arises from various pathogenic mechanisms including gene translocations and fusions. Detection of gene rearrangements using fluorescence in situ hybridization (FISH) is a standard practice for DLBCL diagnosis and guides treatment decisions. High-throughput chromosome conformation capture (Hi-C) DNA sequencing is a next-generation sequencing-based technology to identify genome-wide rearrangements using a single assay. In this study, Hi-C sequencing was performed using FFPE tissues from 159 patients with DLBCL, and identified 746 cancer genes at or proximal to the rearrangement breakpoints with a total of 1903 occurrences. Focusing on clinically important rearrangements, Hi-C detected 102 rearrangements of MYC, BCL2, and/or BCL6 in 92 patients and revealed the fusion partners, including 25 rearrangements missed by FISH. Causes of FISH negative results included FISH-cryptic breakpoints, complex or faint FISH signals, low percentage of FISH positivity, and issues related to tissue fixation. Moreover, in 20 patients (12.6%), Hi-C sequencing detected 22 rearrangements characteristic of other lymphoma types, including CCND1 rearrangements that could lead to reclassification as mantle cell lymphoma. Survival analysis for genome-wide rearrangements using machine learning models identified MYC, PD-L1, CCND1, BCL2, NTRK1/PRCC, RRAS, and FANCE rearrangements with significant prognostic effects in the DLBCL cohort. In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
Pancreas Transplantation for Recipients with Type 2 Diabetes Mellitus: Results of an International Survey
Fridell, Jonathan A. , Uva, Pablo D., Kukla, Aleksandra, Delonais‐Parker, Ava , Mansuri, Rushda Faruk, Axelrod, David, Dunn, Ty, Niederhaus, Silke V. , Parsons, Ronald, Pleass, Henry, Paraskevas, Steven , Rickels, Michael R., Stratta, Robert J., Ventura-Aguiar, Pedro, Fridell, Jonathan A. , Uva, Pablo Daniel , Kukla, Aleksandra , Axelrod, David A. , Dunn, Ty B , Parsons, Ronald F. , Pleass, Henry C. C. , Rickels, Michael R. , Stratta, Robert J. , Ventura‐Aguiar, Pedro , Woodside, Kenneth J. , Lentine, Krista L.

Mayo Clinic

Transplantation Direct | June 7, 2026 | Volume: 12 | Issue: 7 | Pages: e1963

10.1097/txd.0000000000001963 | PMID 42256091 Get It

Background. Pancreas transplantation (PT), historically limited to patients with type 1 diabetes (T1D), is currently performed successfully in selected patients with type 2 diabetes (T2D). However, contemporary practice patterns and eligibility criteria for PT in T2D remain incompletely characterized. Methods. The International Pancreas and Islet Transplant Association Pancreas Transplant Interest Group developed an electronic survey to assess center-level approaches to patient phenotyping, candidacy, and peri- and posttransplant management for PT in patients with T2D. The survey was distributed to international transplant professionals during an International Pancreas and Islet Transplant Association Pre-Congress meeting on June 15, 2025. Results. Thirty-seven participants completed the survey. Most respondents’ programs offer PT for T2D only when a kidney transplant is also indicated. Fewer respondents’ programs also offer PT alone (10%), evaluate T2D candidates on a case-by-case basis (3%), or do not offer PT to patients with T2D (10%). Total daily insulin requirement and body mass index (BMI) were the most selected factors in determining eligibility. Considerable variability existed in metabolic thresholds: 62% of programs reported no C-peptide cutoff, whereas nearly half required a BMI of <30 kg/m 2 for C-peptide-positive candidates. Respondents frequently recommend weight-optimization strategies, including lifestyle modification, glucagon-like peptide-1 receptor agonists, and bariatric surgery for candidates exceeding acceptable BMI thresholds. Surgical technique, induction, and maintenance immunosuppression and early posttransplant glycemic management were largely uniform between T2D and T1D recipients. Conclusions. International practice reflects broad but heterogeneous adoption of PT for T2D, with most participants restricting its use to candidates requiring kidney transplantation and emphasizing integrated clinical phenotyping approaches.
Diagnostic Yield of Cardiac CT to Detect Cardiac Thrombi in Patients With Acute Ischemic Stroke (AIS of HEARTS)
Nio, Shan Sui , Green, Daniel S. , Berry-Noronha, Alexander , Rinkel, Leon A. , Beemsterboer, Chiel F.P. , Hasnain, Md Golam , Planken, R. Nils , Randen, Adriënne van , Al-Hadethi, Sinan , Hilt, Mirre G.M. , Ruhe, Deborah S.A., Boekholdt, S Matthijs, Chew, Beng Lim Alvin , Fridgant, Joshua, Mena-Romo, Luis , Kim, Dong Hyun, Guo, Shuyu, Winders, Joel, Senadeera, Sajith C. , Lim, Anthony , Fink, John, Leung, Melissa , Cordato, Dennis, Spratt, N., Collaborators, on behalf of the AIS of HEARTS, Green, Daniel S , van Randen, Adrienne , Bouma, Berto J , Boekholdt, S Matthijs , Fridgant, Joshua , Mena-Romo, Luis , Alamri, Yassar , Lim, Anthony T , Leung, Melissa , Cordato, Dennis , Parsons, Mark W , Spratt, Neil J , Garcia-Esperon, Carlos , Wu, Teddy Y , Coutinho, Jonathan M , Beemsterboer, Chiel F P , Planken, R Nils , Berry‐Noronha, Alexander , Hasnain, Md Golam , Hilt, Mirre , Ruhe, Deborah, Bouma, Berto J. , Boekholdt, S. Matthijs , Kim, Dong Hyun, Fink, John

Mayo Clinic

Stroke | June 2, 2026 | Volume: 57 | Issue: 8 | Pages: 2408-2416

10.1161/strokeaha.126.055575 | PMID 42227105 Get It

BACKGROUND: Cardiac computed tomography (CT) acquired during the acute stroke imaging protocol is an emerging modality to detect cardiac thrombi. We determined its yield in patients with acute ischemic stroke. METHODS: We performed a 1-stage individual patient data meta-analysis of 4 prospective observational cohorts (AIS of HEARTS [Acute Ischemic Stroke of Heart-Related Embolic Sources Detected on Acute Cardiac CT Scans]), including patients with acute ischemic stroke who underwent ECG-gated or non–ECG-gated cardiac CT between May 2018 and June 2024. We excluded patients with transient ischemic attack or stroke mimics. The primary outcome was the proportion of patients with a thrombus on cardiac CT. Secondary outcomes were additional scan time, radiation dose, comparison with echocardiography, and 90-day outcomes. We performed logistic regression analyses to compare 90-day outcomes between patients with and without thrombus, adjusting for age, sex, history of atrial fibrillation, ischemic heart disease, chronic heart failure, stroke or transient ischemic attack, anticoagulant use, prestroke modified Rankin Scale score, National Institutes of Health Stroke Scale score, large vessel occlusions, and intravenous thrombolysis, as appropriate for each outcome. RESULTS: We included 3919 patients (median age, 74 [interquartile range (IQR), 63–82], 58% male, median National Institutes of Health Stroke Scale score 6 [IQR, 3–12]). Cardiac CT detected a thrombus in 243 (6.2%) patients. Among 1323 patients that underwent both cardiac CT and transthoracic echocardiography, cardiac CT had a higher yield than transthoracic echocardiography (odds ratio, 7.4 [95% CI, 4.0–15.1]; P <0.001). Median additional scan time was 6 minutes (IQR, 5–7) for ECG-gated and 13 seconds (IQR, 12–61) for non–ECG-gated cardiac CT. Median additional radiation dose was 2.9 mSv (IQR, 1.6–4.1). Patients with thrombi had higher 90-day mortality (33% versus 15%, adjusted odds ratio, 1.6 [95% CI, 1.1–2.3]) and worse modified Rankin Scale scores (median modified Rankin Scale score 3 versus 2, adjusted odds ratio, 1.6 [95% CI, 1.2–2.0]), but similar recurrent stroke rates (5% versus 4%, adjusted odds ratio, 1.4 [95% CI, 0.7–2.5]). CONCLUSIONS: Implementing cardiac CT into the acute stroke imaging protocol is feasible, detects thrombi in ≈6% of patients, and has a higher yield than transthoracic echocardiography. Cardiac thrombi were associated with higher mortality, but not higher stroke recurrence. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT07165093.
APOE3-Christchurch variant enhances neurovascular support functions of iPSC-derived mesenchymal stromal cells
Martinez, Paula J. Rodriguez, Yslas, Aria R., Inoue, Yasuteru , Parsons, Tammee M., Baker, Samantha K., Lü, Wenyan, Raulin, Ana‐Caroline , Kanekiyo, Takahisa , Rodriguez Martinez, Paula J, Raulin, Ana-Caroline , Yslas, Aria R.

Mayo Clinic

Frontiers in Molecular Biosciences | June 1, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fmolb.2026.1778856 | PMID 42306774 Get It

Aging and neurodegenerative disorders like Alzheimer’s Disease (AD) are associated with progressive dysfunction of the blood-brain barrier (BBB) and neurovascular unit (NVU), contributing to impaired vascular integrity and neuronal vulnerability. Apolipoprotein E (APOE) is a key regulator of neurovascular function, and the rare APOE3-R136S “Christchurch” variant ( APOE3Ch ) confers protection against AD. Mesenchymal stromal cells (MSCs) represent a promising cell-based therapy for the treatment of neurodegenerative diseases due to their paracrine effect exerted on vascular and neural cells. To investigate how APOE3Ch influences MSC-mediated neurovascular support, we used isogenic iPSC-derived MSCs (iMSCs) with homozygous APOE3Ch or APOE3 . We found that APOE3Ch iMSCs have stronger immunosuppressive effect on LPS-induced NFκB activation of THP1 cells. APOE3Ch iMSCs also enhanced endothelial barrier resistance and angiogenic capacity compared to APOE3 iMSCs when directly co-cultured with endothelial cells. In addition, conditioned medium from APOE3Ch iMSCs promoted neurite outgrowth more efficiently than that from APOE3 iMSCs. Metabolic profiling revealed differences between APOE3Ch and APOE3 iMSCs, suggesting altered metabolic resilience. Together, these findings demonstrate that iMSCs support vascular and neuronal function through paracrine mechanisms and suggest that APOE3Ch variant improves specific aspects of MSC-mediated neurovascular support. This work highlights the potential of combining MSC-based therapies with protective APOE variants to target BBB and NVU dysfunction in aging and neurodegeneration.
A single-arm, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study.
Ruddy, Kathryn Jean, Heiling, Hillary, Rozenblit, Mariya, Dees, Elizabeth Claire , Frey, Anna , Ossing, Sarah, Koegel, Susan, LaScala, Jamie, Brown, Thelma, Tolaney, S M, Carey, L, Krop, Ian E., Tayob, Nabihah, Winer, Eric P., Rimawi, Mothaffar, Parsons, Heather A. , Lin, Nancy U., Morganti, Stefania , Ruddy, Kathryn J. , Heiling, Hillary , Rozenblit, Mariya , Stoeckle, James Hart , Pradhan, Deepti , Carey, Lisa A. , Krop, Ian E. , Tayob, Nabihah , Winer, Eric P. , Rimawi, Mothaffar, Lin, Nancy U.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps1147 Get It

TPS1147 Background: Due to dramatic improvements in neoadjuvant and adjuvant HER2-directed therapy (tx), most patients (pts) with early HER2+ breast cancer are cured. As a result, over half of pts newly diagnosed with HER2+ metastatic breast cancer (MBC) now present with de novo stage IV disease. Anti-HER2 tx has also significantly extended survival for pts with HER2+ MBC, with a subgroup of exceptional responders alive many years (yrs) after diagnosis. However, the paradigm for HER2+ MBC remains non-curative, and pts receive tx indefinitely with significant toxicities and costs. The SAPPHO study is investigating whether an intensification approach of sequential, non-cross resistant anti-HER2 tx followed by tx discontinuation is associated with long-term disease control in pts with HER2+ MBC. Methods: SAPPHO is an open-label, phase II, single-arm trial testing a sequential regimen of non-cross resistant, HER2-targeted tx with curative intent in pts with de novo HER2+ MBC. Eligible pts must have biopsy-proven, de novo MBC with high HER2 expression (3+ by immunohistochemistry). Pts with brain metastases are eligible upon receipt of local tx. Treatment consists of an induction regimen (trastuzumab-pertuzumab-taxane [THP] x 4 cycles, followed by trastuzumab deruxtecan [TDXd] x 6 cycles, followed by trastuzumab emtansine [TDM1]-tucatinib x 4 cycles), followed by a maintenance regimen (HP-tucatinib for 1 yr). Given results from DESTINY-Breast09, the sequence of TDXd-P x 6 cycles followed by THP x 4 followed by TDM1-tucatinib x 4 can be chosen as alternative induction tx per investigator and patient choice. Pts who remain progression-free after completing maintenance will stop all anti-HER2 tx. Endocrine tx will be continued for pts with hormone receptor+/HER2+ tumors. Tumor specimens from breast and a metastatic site are collected at baseline and the end of induction. Serial plasma samples for ctDNA analysis are collected at baseline, during treatment, and during follow-up. The primary endpoint is the probability of being progression-free and off anti-HER2 tx 4 yrs from the start of induction. With a sample size of 72 pts, the study is designed to have 91% power to reject the null hypothesis that the probability of being off anti-HER2 tx and progression-free is less than 24%, with an alternative hypothesis of 40%. Key secondary endpoints are overall survival, overall response rate by modified RECIST 1.1 after induction, and safety. Correlative endpoints include the relationship between ctDNA dynamics and outcomes. Patient-reported outcomes will be analyzed, including quality of life, illness intrusiveness, financial toxicity, anxiety, distress about cancer progression, perception of benefit and risk of progression. SAPPHO began enrollment in Q3 2024, and the study is open at 4 US sites within the Translational Breast Cancer Research Consortium (NCT05721248). Clinical trial information: NCT05721248 .
Solitary plasmacytoma of bone (SPB): Randomized phase III trial to evaluate treatment with adjuvant systemic treatment and zoledronic acid (ZA) versus zoledronic acid after definitive radiation treatment (Alliance A061402)
Sborov, Douglas, Mahindra, Anuj, Suman, Vera J. , Manasanch, Elisabet, Kapoor, Prashant , Kovacsovics, Tibor, Rodriguez, Cesar, Parsons, Benjamin, Najera, Jose, Goldman, Lyle, Carlisle, Destin, Wen, Yujia, Dinner, Shira, Galinsky, Ilene, Kennedy, LeAnne , Omel, James, McCarthy, Philip, Usmani, Saad, Richardson, Paul G. , Suman, Vera , Sborov, Douglas W. , Manasanch, Elisabet E. , Rodriguez, Cesar, Parsons, Benjamin, Najera, Jose Eugenio, Galinsky, Ilene , Usmani, Saad Z. , Richardson, Paul Gerard Guy

Mayo Clinic

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9453152/v1 Get It

Abstract Solitary plasmacytoma of bone (SPB) is a localized plasma cell neoplasm associated with a substantial risk of progression to multiple myeloma (MM), yet the role of adjuvant systemic therapy following definitive radiation therapy (RT) remains undefined. We conducted a randomized phase III trial (Alliance A061402) to evaluate whether the addition of systemic therapy with ixazomib, lenalidomide, and dexamethasone (IXA-LEN-DEX) to zoledronic acid (ZA) improves outcomes compared with ZA alone in patients with SPB and minimal (< 10%) bone marrow plasma cell involvement following RT. Patients were randomized to receive six 28-day cycles of IXA-LEN-DEX-ZA or ZA alone. The primary endpoint was time to progression (TTP) to MM. The study was closed early due to poor accrual after enrolling 11 patients (IXA-LEN-DEX-ZA, n = 5; ZA, n = 6). All patients completed RT and planned treatment without dose reductions. The combination regimen was well tolerated, with limited grade ≥ 3 toxicities, including hypophosphatemia and lymphopenia. At follow-up extending beyond 4 years, the 1- and 4-year progression rates to MM in the IXA-LEN-DEX-ZA arm were 0% and 33%, respectively, compared with 37.5% and 58.3% at 1 and 2 years in the ZA-alone arm. Although underpowered, these findings demonstrate the feasibility and tolerability of an all-oral adjuvant systemic regimen in SPB and provide prospective data supporting further investigation of systemic strategies to delay progression to MM.
Abstract 4661: Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53
Lyu, Beibei, Xu-Monette, Zijun Yidan, Zhao, Xiaoxian X., Chen, Ming, Visco, Carlo, Dybkaer, Karen, Wang, Chang , Au, Qingyan , Nunns, Harry , Pan, Zenggang, Montes-Moreno, Santiago, Bernal-Mizrachi, Leon, Zu, Youli , Zhang, Shanxiang , Chen, Weina , Li, Yong, Zu, Youli , Xu‐Monette, Zijun Y. , Hsi, Eric D. , Visco, Carlo , Tzankov, Alexandar , Dybkær, Karen , Wang, Mu‐En , Pan, Zenggang , Parsons, Benjamin M. , Montes‐Moreno, Santiago , Zhan, Fenghuang , Møller, Michael , Bernal‐Mizrachi, Leon , Bhagat, Govind , Young, Ken H.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4661-4661

10.1158/1538-7445.am2026-4661 Get It

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma. Previous studies have shown that DLBCL cells are susceptible to GPX4 (Glutathione peroxidase 4)-regulated ferroptosis, an iron-dependent type of programmed cell death characterized by increased reactive oxygen species and excessive lipid peroxidation. In addition to GPX4, FSP1 (Ferroptosis suppressor protein 1, previously known as AIFM2) is a glutathione-independent repressor of ferroptosis that has shown prognostic significance in solid tumors. In this study, we aimed to reveal the significance of GPX4 and FSP1 in DLBCL. Patients and Methods: We performed immunohistochemistry (IHC) for GPX4 and FSP1 in a large cohorts of patients with de novo DLBCL, and evaluated their cytoplasmic and nuclear expression. Prognostic analysis was performed for FSP1 and GPX4 expression in patients treated with rituximab (R)-CHOP or CHOP chemotherapy, respective of TP53 mutation status, as p53 regulates ferroptosis and TP53 mutation is associated with poorer prognosis in DLBCL. Results: FSP1 expression with a ≥10% cutoff was positive in 42.3% of DLBCL cases. Patients with TP53 mutations had a non-significant trend of higher mean FSP1 expression than those with wild-type (Wt) TP53 (P=0.11). Prognostic analysis revealed that cytoplasmic FSP1+ expression was associated with significantly poorer overall survival and progression-free survival in Wt-TP53 DLBCLs treated with R-CHOP (P=0.016 and P=0.003, respectively), and only showed non-significant unfavorable trends in TP53 mutated DLBCLs and patients treated with CHOP. In contrast, GPX4 expression did not show a significant unfavorable prognostic effect in DLBCL, and in fact, was associated with a non-significant trend of better survival. Previously we have quantified immune cell abundance and PD-1/PD-L1 expression in the tumor microenvironment of the study cohort using multiplex fluorescent IHC. Correlative analysis found that FSP1+ patients had significantly higher mean and median abundance of CD68+ cells (both M1 and M2 macrophages) and CD11c+ cells than FSP1- patients. Further analysis in Wt-TP53 and mutated TP53 subcohorts found that only in the TP53 mutated DLBCL subcohort, FSP1 expression was associated with significantly higher mean and median CD163-CD68+ (M1) and overall CD68+ macrophages, whereas in the Wt-TP53 DLBCL subcohort, FSP1 expression was associated with significantly higher median (but not mean) CD163+CD68+ (M2) macrophages and CD11c+ cells. Summary: Cytoplasmic FSP1 expression but not GPX4 had significantly adverse prognostic effect in patients with Wt-TP53 DLBCL treated with standard immunochemotherapy. Our results also suggest that in addition to ferroptosis regulation, macrophage abundance was relevant for the prognostic effects of FSP1 expression. Citation Format: Beibei Lyu, Zijun Xu-Monette, Xiaoxian X. Zhao, Eric D. Hsi, Ming Chen, Carlo Visco, Alexandar Tzankov, Karen Dybkaer, Mu-En Wang, Chang Wang, Qingyan Au, Harry Nunns, Zenggang Pan, Benjamin Parsons, Santiago Montes-Moreno, Fenghuang Zhan, Michael B. Møller, Leon Bernal-Mizrachi, Youli Zu, Shanxiang Zhang, Weina Chen, Govind Bhagat, Yong Li, KEN H. YOUNG. Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4661.